Indefinite Delivery Contract SPE2DB24D9250

This indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 single-award IDC, under the SPE2DB program, runs through December 31, 2025 and allows DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support the recurring medical supply needs of military health facilities worldwide.

The IDC covers a vast array of pharmaceutical items, from common medications like antibiotics and pain relievers to specialized drugs, biologics, and medical consumables. Key products supplied include flumazenil injections, prednisone tablets, ampicillin injections, clotrimazole cream, epinephrine auto-injectors, contraceptives, oncology drugs, and specialty medications. These products are primarily delivered to the DLA's Medical Supply Chain division, which then distributes them to various Department of Defense healthcare facilities globally. This IDC complements DMS Pharmaceutical Group's separate prime vendor contracts for direct distribution of prescription drugs and pharmacy services to DoD sites, solidifying the company's position as a crucial supplier in the federal pharmaceutical supply chain.